Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
暂无分享,去创建一个
D. Stram | J. Maris | R. Gerbing | P. White | M. Hogarty | G. Brodeur | C. Guo
[1] D. Stram,et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K K Matthay,et al. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .
[3] D. Stram,et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas , 1999, Oncogene.
[4] K K Matthay,et al. Molecular biology of neuroblastoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Speleman,et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization , 1998, Genes, chromosomes & cancer.
[6] A. Jauch,et al. Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis. , 1997, European journal of cancer.
[7] Nick Bown,et al. Comparative genomic hybridization study of primary neuroblastoma tumors , 1997, Genes, chromosomes & cancer.
[8] K. Matthay,et al. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. , 1997, The American journal of pathology.